BioSpace News Archive

Alvotech Holdings SA announced that it has entered into an amendment and restatement agreement with bondholders of its $300m covertible bond issued on December 14, 2018.

Osmotica Pharmaceuticals, plc, a fully integrated biopharmaceutical company, announced that it has entered into a definitive Purchase and Sale Agreement with Alora Pharmaceuticals, LLC pursuant to which Alora will acquire Osmotica’s portfolio of legacy products and its Marietta, Georgia manufacturing facility, for up to $170 million.

The CHMP adopted a positive opinion based on results from the pivotal Phase 2 KarMMa study evaluating the efficacy and safety of Abecma in 128 patients with heavily pre-treated and highly refractory multiple myeloma.

Ampersand Capital Partners announced that it has completed the sale of Nexcelom Bioscience, one of its portfolio companies and a leading provider of automated cell counting solutions, to PerkinElmer for $260 million in cash.

InnoCare, a leading biopharmaceutical company focusing on cancer and autoimmune diseases, announced that China’s National Medical Products Administration has approved the initiation of a Phase I clinical trial of ICP-033, the Company’s novel RTK inhibitor and its sixth innovative drug to enter clinical development.

Antibe Therapeutics Inc., a clinical-stage company leveraging its unique hydrogen sulfide platform to develop next-generation safer therapies to target inflammation in a wide range of health conditions, announced a strategic collaboration with Dalriada Drug Discovery to develop new drug candidates and fortify Antibe’s intellectual property position for its current pipeline.

Bristol Myers Squibb announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended approval of Opdivo for the adjuvant treatment of adult patients with esophageal or gastroesophageal junction cancer who have residual pathologic disease following prior neoadjuvant chemoradiotherapy.

Jazz Pharmaceuticals plc today announced that the U.S. Food and Drug Administration (FDA) has recognized seven years of Orphan Drug Exclusivity for Xywav.

OcuTerra Therapeutics, Inc . today announced the appointment of David J. Tanzer, MD, as Chief Medical Officer and Executive Vice President, Clinical and Medical Affairs.

Early detection of disease can mean the difference between life and death for a person, especially in the case of serious illness.